Gadopentetate dimeglumine

Gd(DTPA)(H20)]2 Gadopentetate dimeglumine Magnevist3 Schering (Germany) Extracellular... 

Pediconi, R, Catalano, C., Occhiato, R., et al. (2005) Breast lesion detection and characterization at contrast-enhanced MR mammography gadobenate dimeglumine versus gadopentetate dimeglumine. Radiology, 237, 45-56. 

Knopp, M.V., Bourne, M.W., Sardanelli, R, et al, (2003) Gadobenate dimeglumine-enhanced MRI of the breast analysis of dose response and comparison with gadopentetate dimeglumine. American Journal of... 

Gadopentetate dimeglumine (1 ml mixed with 4 ml of 5% saline) has been used in myelocisternography in four patients (aged 28-62 years) to demonstrate the exact site of cerebrospinal fluid (CSF) leakage in patients with CSF rhinorrhea (20). All tolerated the examination without adverse effects or complications. 

Gadopentetate dimeglumine (Magnavist) Linear Ionic 22.1 10 minutes 0.4... 

Kaufman JA, Geller SC, Waltman AC. Renal insufficiency gadopentetate dimeglumine as a radiographic contrast agent during peripheral vascular interventional procedures. Radiology 1996 198 579-581. 

Figure 13-21 MRI of the brain of a 36-year-old patient with a single episode of acute weakness. A. T,-weighted axial image without contrast agent taken 3 days later. B. Ti-weighted image after intravenous injection of gadopentetate dimeglumine, which has concentrated in the left frontal lobe (arrow). The patient was diagnosed as having a cerebrovascular accident. (Courtesy of Berlex Laboratories. Inc.)...

Gadopentetate dimeglumine 46. lodamide meglumine 24% (11.1% iodine) lodamide meglumine 65%... 

Youk JH, Lee JM, Kim CS (2004) MRI for detection of hepatocellular carcinoma comparison of mangafodipir trisodium and gadopentetate dimeglumine contrast agents. AJR Am J Roentgenol 183 1049-1054... 

Hricak H,Hamm B,Semelka RC,Cann CE,Nauert T,Secaf E, Stern JL, Wolf KJ (1991) Carcinoma of the uterus use of gadopentetate dimeglumine in MR imaging. Radiology 181 95-106... 

In a retrospective case series of 36 patients exposed to gadopentetate dimeglumine, there was a dose- and time-related relation to nephrogenic systemic fibrosis in patients with chronic kidney disease, all but one of whom were on dialysis. They had been exposed to median cumulative volumes of gadopentetate dimeglumine of 35, 40, 85, and 117.5 ml over 3, 12, and 24 months and up to 11 years before onset. Those who received higher cumulative and total doses had a higher risk than those who received lower doses (OR=1.2). In 20 patients who died, there was a median interval of 18 months between the onset of symptoms and death [33]. 

---